Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of U.S. Studies.

Cho-Reyes S, Celli BR, Dembek C, Yeh K, Navaie M.

Chronic Obstr Pulm Dis. 2019 Jul 24;6(3):267-280. doi: 10.15326/jcopdf.6.3.2018.0168. Review.

2.

It is time for the world to take COPD seriously: a statement from the GOLD board of directors.

Halpin DMG, Celli BR, Criner GJ, Frith P, López Varela MV, Salvi S, Vogelmeier CF, Chen R, Mortimer K, Montes de Oca M, Aisanov Z, Obaseki D, Decker R, Agusti A.

Eur Respir J. 2019 Jul 4;54(1). pii: 1900914. doi: 10.1183/13993003.00914-2019. Print 2019 Jul. No abstract available.

PMID:
31273036
3.

Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial.

Celli BR, Anderson JA, Brook R, Calverley P, Cowans NJ, Crim C, Dixon I, Kim V, Martinez FJ, Morris A, Newby DE, Yates J, Vestbo J.

BMJ Open Respir Res. 2019 May 4;6(1):e000431. doi: 10.1136/bmjresp-2019-000431. eCollection 2019.

4.

Predictors of Nebulized Arformoterol Treatment: A Retrospective Analysis of Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease.

Gilmer TP, Celli BR, Xu Z, Cho-Reyes S, Dembek C, Navaie M.

COPD. 2019 Apr;16(2):140-151. doi: 10.1080/15412555.2019.1618256. Epub 2019 Jun 19.

PMID:
31215259
5.

Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.

Celli BR, Navaie M, Xu Z, Cho-Reyes S, Dembek C, Gilmer TP.

Int J Chron Obstruct Pulmon Dis. 2019 May 15;14:1019-1031. doi: 10.2147/COPD.S199251. eCollection 2019.

6.

Benralizumab for the Prevention of COPD Exacerbations.

Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA and TERRANOVA Study Investigators.

N Engl J Med. 2019 May 20. doi: 10.1056/NEJMoa1905248. [Epub ahead of print]

PMID:
31112385
7.

Enriched Systemic Biomarkers in Symptomatic Unobstructed Smokers: Moving Forward?

Rodriguez-Roisin R, Celli BR.

Chest. 2019 May;155(5):886-887. doi: 10.1016/j.chest.2019.02.314. No abstract available.

PMID:
31060699
8.

Regional differences in rate of FEV1 decline in COPD: lessons from SUMMIT.

Celli BR, Anderson JA, Brook RD, Calverley PMA, Cowans NJ, Crim C, Martinez F, Newby DE, Yates J, Vestbo J.

Eur Respir J. 2019 Jun 27;53(6). pii: 1900278. doi: 10.1183/13993003.00278-2019. Print 2019 Jun. No abstract available.

PMID:
30923182
9.

Reply to Pouwels et al.: Confounding Factors Affecting sRAGE as a Biomarker for Chronic Obstructive Pulmonary Disease.

Stockley RA, Halpin D, Celli BR, Singh D.

Am J Respir Crit Care Med. 2019 Jul 1;200(1):114-115. doi: 10.1164/rccm.201903-0573LE. No abstract available.

10.

External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study.

Almagro P, Martínez-Camblor P, Miravitlles M, Rodríguez-Carballeira M, Navarro A, Lamprecht B, Ramirez-Garcia Luna AS, Kaiser B, Alfageme I, Casanova C, Esteban C, Soler-Cataluña JJ, de-Torres JP, Celli BR, Marin JM, Ter Riet G, Sobradillo P, Lange P, Garcia-Aymerich J, Anto JM, Turner AM, Han MK, Langhammer A, Sternberg A, Leivseth L, Bakke P, Johannessen A, Oga T, Cosío B, Ancochea J, Echazarreta A, Roche N, Burgel PR, Sin DD, Puhan MA, Soriano JB; 3CIA collaboration.

COPD. 2019 Feb;16(1):8-17. doi: 10.1080/15412555.2018.1484440. Epub 2019 Mar 14.

PMID:
30870059
11.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C.

Eur Respir J. 2019 May 18;53(5). pii: 1900164. doi: 10.1183/13993003.00164-2019. Print 2019 May. Review.

PMID:
30846476
12.

Impact of pre-enrolment medication use on clinical outcomes in SUMMIT.

Vestbo J, Dransfield M, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez F, Newby DE, Yates J, Lange P.

ERJ Open Res. 2019 Feb 25;5(1). pii: 00203-2018. doi: 10.1183/23120541.00203-2018. eCollection 2019 Feb.

13.

Patient Preferences for Endobronchial Valve Treatment of Severe Emphysema.

Mansfield C, Sutphin J, Shriner K, Criner GJ, Celli BR.

Chronic Obstr Pulm Dis. 2018 Dec 11;6(1):51-63. doi: 10.15326/jcopdf.6.1.2018.0147.

14.

The Prevalence of Obstructive Lung Disease in a Lung Cancer Screening Cohort: Analysis of the National Lung Screening Trial-American College of Radiology Image Network Cohort.

de-Torres JP, Wisnivesky JP, Bastarrika G, Wilson DO, Celli BR, Zulueta JJ.

Ann Am Thorac Soc. 2019 May;16(5):641-644. doi: 10.1513/AnnalsATS.201811-817RL. No abstract available.

PMID:
30673510
15.

Using the Peripheral Blood Eosinophil Count to Manage Patients with Chronic Obstructive Pulmonary Disease.

Celli BR, Criner GJ.

Ann Am Thorac Soc. 2019 Mar;16(3):301-303. doi: 10.1513/AnnalsATS.201810-729PS. No abstract available.

PMID:
30620613
16.

Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation.

Stockley RA, Halpin DMG, Celli BR, Singh D.

Am J Respir Crit Care Med. 2019 May 15;199(10):1195-1204. doi: 10.1164/rccm.201810-1860SO.

PMID:
30592902
17.

Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee.

Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, Fabbri LM, Frith P, Halpin DMG, Han M, Montes de Oca M, Nishimura M, O'Donnell D, Papi A, Pavord I, Roche N, Rodriguez-Roisin R, Salvi S, Singh D, Sin DD, Stockley R, López Varela MV, Vestbo J, Vogelmeier CF, Washko G, Wedzicha JA, Celli BR.

Ann Am Thorac Soc. 2019 Jan;16(1):29-39. doi: 10.1513/AnnalsATS.201808-557PS. No abstract available.

PMID:
30427736
18.

Failure of Low-Dose Theophylline to Prevent Exacerbations in Patients With COPD.

Criner GJ, Celli BR.

JAMA. 2018 Oct 16;320(15):1541-1542. doi: 10.1001/jama.2018.14295. No abstract available.

PMID:
30326108
19.

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.

Tashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A.

Respir Res. 2018 Oct 5;19(1):196. doi: 10.1186/s12931-018-0874-0.

20.

Supplementation with Qter® and Creatine improves functional performance in COPD patients on long term oxygen therapy.

De Benedetto F, Pastorelli R, Ferrario M, de Blasio F, Marinari S, Brunelli L, Wouters EFM, Polverino F, Celli BR; Interdisciplinary Association for Research in Lung Disease (AIMAR) Study Group.

Respir Med. 2018 Sep;142:86-93. doi: 10.1016/j.rmed.2018.08.002. Epub 2018 Aug 7.

PMID:
30170808
21.

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease.

Adamson PD, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Dixon IJ, Martinez FJ, Newby DE, Vestbo J, Yates JC, Mills NL.

J Am Coll Cardiol. 2018 Sep 4;72(10):1126-1137. doi: 10.1016/j.jacc.2018.06.051. Erratum in: J Am Coll Cardiol. 2018 Oct 30;72(18):2282.

22.

The Course of Lung Function in Middle-aged Heavy Smokers: Incidence and Time to Early Onset of Chronic Obstructive Pulmonary Disease.

Petersen H, Sood A, Polverino F, Owen CA, Pinto-Plata V, Celli BR, Tesfaigzi Y.

Am J Respir Crit Care Med. 2018 Dec 1;198(11):1449-1451. doi: 10.1164/rccm.201805-0861LE. No abstract available.

PMID:
30114375
23.

Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial.

Byrd JB, Newby DE, Anderson JA, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez FJ, Vestbo J, Yates J, Brook RD; SUMMIT Investigators.

Eur Heart J. 2018 Sep 1;39(33):3128-3134. doi: 10.1093/eurheartj/ehy451.

PMID:
30101300
24.

The effect of emphysema on readmission and survival among smokers with heart failure.

Kohli P, Staziaki PV, Janjua SA, Addison DA, Hallett TR, Hennessy O, Takx RAP, Lu MT, Fintelmann FJ, Semigran M, Harris RS, Celli BR, Hoffmann U, Neilan TG.

PLoS One. 2018 Jul 30;13(7):e0201376. doi: 10.1371/journal.pone.0201376. eCollection 2018.

25.

Prevalence of paradoxical bronchoconstriction after inhaled albuterol.

Schissler AJ, Celli BR.

Respir Med. 2018 Aug;141:100-102. doi: 10.1016/j.rmed.2018.06.028. Epub 2018 Jun 30.

PMID:
30053954
26.

Pharmacological Therapy of COPD: Reasons for Optimism.

Celli BR.

Chest. 2018 Dec;154(6):1404-1415. doi: 10.1016/j.chest.2018.07.005. Epub 2018 Jul 17. Review.

PMID:
30028967
27.

Improving Our Aim: Targeting Therapy with Roflumilast in Patients with Severe and Very Severe Chronic Obstructive Pulmonary Disease.

Celli BR.

Am J Respir Crit Care Med. 2018 Nov 15;198(10):1242-1244. doi: 10.1164/rccm.201806-1051ED. No abstract available.

PMID:
29953246
28.

Targeting dyspnoea in patients with very severe COPD: Practical precision medicine.

Celli BR.

Respirology. 2018 Dec;23(12):1086-1087. doi: 10.1111/resp.13359. Epub 2018 Jun 25. No abstract available.

29.

A Disintegrin and Metalloproteinase Domain-8: A Novel Protective Proteinase in Chronic Obstructive Pulmonary Disease.

Polverino F, Rojas-Quintero J, Wang X, Petersen H, Zhang L, Gai X, Higham A, Zhang D, Gupta K, Rout A, Yambayev I, Pinto-Plata V, Sholl LM, Cunoosamy D, Celli BR, Goldring J, Singh D, Tesfaigzi Y, Wedzicha J, Olsson H, Owen CA.

Am J Respir Crit Care Med. 2018 Nov 15;198(10):1254-1267. doi: 10.1164/rccm.201707-1331OC.

30.

COPD: time to improve its taxonomy?

Celli BR, Agustí A.

ERJ Open Res. 2018 Feb 16;4(1). pii: 00132-2017. doi: 10.1183/23120541.00132-2017. eCollection 2018 Jan.

31.

Pulmonary arterial enlargement predicts long-term survival in COPD patients.

de-Torres JP, Ezponda A, Alcaide AB, Campo A, Berto J, Gonzalez J, Zulueta JJ, Casanova C, Rodriguez-Delgado LE, Celli BR, Bastarrika G.

PLoS One. 2018 Apr 25;13(4):e0195640. doi: 10.1371/journal.pone.0195640. eCollection 2018.

32.

Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease.

Guerra B, Haile SR, Lamprecht B, Ramírez AS, Martinez-Camblor P, Kaiser B, Alfageme I, Almagro P, Casanova C, Esteban-González C, Soler-Cataluña JJ, de-Torres JP, Miravitlles M, Celli BR, Marin JM, Ter Riet G, Sobradillo P, Lange P, Garcia-Aymerich J, Antó JM, Turner AM, Han MK, Langhammer A, Leivseth L, Bakke P, Johannessen A, Oga T, Cosio B, Ancochea-Bermúdez J, Echazarreta A, Roche N, Burgel PR, Sin DD, Soriano JB, Puhan MA; 3CIA collaboration.

BMC Med. 2018 Mar 2;16(1):33. doi: 10.1186/s12916-018-1013-y.

33.

Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort.

Divo MJ, Celli BR, Poblador-Plou B, Calderón-Larrañaga A, de-Torres JP, Gimeno-Feliu LA, Bertó J, Zulueta JJ, Casanova C, Pinto-Plata VM, Cabrera-Lopez C, Polverino F, Carmona Píréz J, Prados-Torres A, Marin JM; EpiChron—BODE Collaborative Group.

PLoS One. 2018 Feb 22;13(2):e0193143. doi: 10.1371/journal.pone.0193143. eCollection 2018.

34.

COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series).

Polverino F, Celli BR, Owen CA.

Pulm Circ. 2018 Jan-Mar;8(1):2045894018758528. doi: 10.1177/2045894018758528.

35.

Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial.

Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Hartley BF, Martinez FJ, Newby DE, Pragman AA, Vestbo J, Yates JC, Niewoehner DE; SUMMIT Investigators.

Am J Respir Crit Care Med. 2018 Jul 1;198(1):51-57. doi: 10.1164/rccm.201711-2239OC.

PMID:
29442524
36.

Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype.

Celli BR, Locantore N, Tal-Singer R, Riley J, Miller B, Vestbo J, Yates JC, Silverman EK, Owen CA, Divo M, Pinto-Plata V, Wouters EFM, Faner R, Agusti A; ECLIPSE Study Investigators.

Eur Respir J. 2018 Feb 7;51(2). pii: 1702146. doi: 10.1183/13993003.02146-2017. Print 2018 Feb.

37.

At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease.

Martinez FJ, Han MK, Allinson JP, Barr RG, Boucher RC, Calverley PMA, Celli BR, Christenson SA, Crystal RG, Fagerås M, Freeman CM, Groenke L, Hoffman EA, Kesimer M, Kostikas K, Paine R 3rd, Rafii S, Rennard SI, Segal LN, Shaykhiev R, Stevenson C, Tal-Singer R, Vestbo J, Woodruff PG, Curtis JL, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1540-1551. doi: 10.1164/rccm.201710-2028PP. No abstract available. Erratum in: Am J Respir Crit Care Med. 2018 Dec 1;198(11):1463.

38.

β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT.

Dransfield MT, McAllister DA, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Gallot N, Martinez FJ, Scanlon PD, Yates J, Vestbo J, Newby DE; SUMMIT Investigators.

Ann Am Thorac Soc. 2018 May;15(5):608-614. doi: 10.1513/AnnalsATS.201708-626OC.

PMID:
29406772
39.

Cigarette smoking and response to inhaled corticosteroids in COPD.

Bhatt SP, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez FJ, Newby DE, Vestbo J, Yates JC, Dransfield MT.

Eur Respir J. 2018 Jan 18;51(1). pii: 1701393. doi: 10.1183/13993003.01393-2017. Print 2018 Jan. No abstract available.

40.

Smoking In COPD Patients: A New Clinical Phenotype?

Carrión Valero F, Paulos Dos Santos S, Celli BR.

Arch Bronconeumol. 2018 May;54(5):249-250. doi: 10.1016/j.arbres.2017.10.021. Epub 2017 Dec 6. English, Spanish. No abstract available.

41.

Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD.

Casanova C, Celli BR, de-Torres JP, Martínez-Gonzalez C, Cosio BG, Pinto-Plata V, de Lucas-Ramos P, Divo M, Fuster A, Peces-Barba G, Calle-Rubio M, Solanes I, Aguero R, Feu-Collado N, Alfageme I, De Diego A, Romero A, Balcells E, Llunell A, Galdiz JB, Marin M, Moreno A, Cabrera C, Golpe R, Lacarcel C, Soriano JB, López-Campos JL, Soler-Cataluña JJ, Marin JM.

Eur Respir J. 2017 Nov 22;50(5). pii: 1701162. doi: 10.1183/13993003.01162-2017. Print 2017 Nov.

42.

A simple algorithm for the identification of clinical COPD phenotypes.

Burgel PR, Paillasseur JL, Janssens W, Piquet J, Ter Riet G, Garcia-Aymerich J, Cosio B, Bakke P, Puhan MA, Langhammer A, Alfageme I, Almagro P, Ancochea J, Celli BR, Casanova C, de-Torres JP, Decramer M, Echazarreta A, Esteban C, Gomez Punter RM, Han MK, Johannessen A, Kaiser B, Lamprecht B, Lange P, Leivseth L, Marin JM, Martin F, Martinez-Camblor P, Miravitlles M, Oga T, Sofia Ramírez A, Sin DD, Sobradillo P, Soler-Cataluña JJ, Turner AM, Verdu Rivera FJ, Soriano JB, Roche N; Initiatives BPCO, EABPCO, Leuven and 3CIA study groups.

Eur Respir J. 2017 Nov 2;50(5). pii: 1701034. doi: 10.1183/13993003.01034-2017. Print 2017 Nov.

43.

Deterioration of Limb Muscle Function during Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Abdulai RM, Jensen TJ, Patel NR, Polkey MI, Jansson P, Celli BR, Rennard SI.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):433-449. doi: 10.1164/rccm.201703-0615CI. Review.

44.

Survival of Lung Transplant Candidates With COPD: BODE Score Reconsidered.

Reed RM, Cabral HJ, Dransfield MT, Eberlein M, Merlo CA, Mulligan MJ, Netzer G, Sanchez PG, Scharf SM, Sin DD, Celli BR.

Chest. 2018 Mar;153(3):697-701. doi: 10.1016/j.chest.2017.10.008. Epub 2017 Oct 17.

45.

Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients.

Zagaceta J, Bastarrika G, Zulueta JJ, Colina I, Alcaide AB, Campo A, Divo M, Casanova C, Marin JM, Pinto-Plata VM, Celli BR, de-Torres JP.

Respir Res. 2017 Sep 29;18(1):175. doi: 10.1186/s12931-017-0658-y.

46.

Dissecting COPD exacerbations: time to rethink our definition.

Celli BR.

Eur Respir J. 2017 Sep 27;50(3). pii: 1701432. doi: 10.1183/13993003.01432-2017. Print 2017 Sep. No abstract available.

47.

Chronic Obstructive Pulmonary Disease: Breathing New Life into Old Cardiovascular Drugs?

Polverino F, Celli BR, Owen CA.

Ann Am Thorac Soc. 2017 Nov;14(11):1718. doi: 10.1513/AnnalsATS.201707-613LE. No abstract available.

PMID:
28950067
48.

Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.

Crim C, Calverley PMA, Anderson JA, Holmes AP, Kilbride S, Martinez FJ, Brook RD, Newby DE, Yates JC, Celli BR, Vestbo J; SUMMIT investigators.

Respir Med. 2017 Oct;131:27-34. doi: 10.1016/j.rmed.2017.07.060. Epub 2017 Aug 1.

PMID:
28947039
49.

Patient Related Outcomes-BODE (PRO-BODE): A composite index incorporating health utilization resources predicts mortality and economic cost of COPD in real life.

Dal Negro RW, Celli BR.

Respir Med. 2017 Oct;131:175-178. doi: 10.1016/j.rmed.2017.08.019. Epub 2017 Aug 24.

PMID:
28947025
50.

Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk.

Calverley PMA, Anderson JA, Brook RD, Crim C, Gallot N, Kilbride S, Martinez FJ, Yates J, Newby DE, Vestbo J, Wise R, Celli BR; SUMMIT (Study to Understand Mortality and Morbidity) Investigators.

Am J Respir Crit Care Med. 2018 Jan 1;197(1):47-55. doi: 10.1164/rccm.201610-2086OC.

PMID:
28737971

Supplemental Content

Loading ...
Support Center